I want to obtain biological material for research purposes, should I consider the Convention on Biological Diversity and the Nagoya Protocol?

Case study Product law 23 April 2026

Client

Global chemicals and Life Sciences group

The situation

The Convention on Biological Diversity and the Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilisation (ABS – Access and Benefit Sharing) are regulations of which many businesses in the Life Sciences, chemicals and research sectors are unaware or know too little about. Yet their violation carries both legal and reputational risk. A global chemicals group was planning to obtain isolated sugar for research purposes. The question was: does the planned operation trigger any obligations under the Convention on Biological Diversity, the Nagoya Protocol or other Polish regulations? Is the consent of the country of origin of the material required, and is a benefit-sharing agreement (MAT) needed?

Our role

We conducted a legal analysis of the client’s planned operation against obligations arising from the Convention on Biological Diversity, the Nagoya Protocol, EU Regulation No 511/2014 on access and benefit sharing, and Polish law. This is a niche but growing area of law at the intersection of environmental law, intellectual property law and product law in which we were among the first to identify the need for advisory services on the Polish market and among the first to build advisory expertise.

The result

This is an example of advisory work in a completely new regulatory area where even large global companies do not always know that the regulations apply to them at all. Being a pioneer in this kind of advisory on the Polish market is part of our strategy: we track regulatory trends across Europe and globally and build expertise before clients start asking questions.

Does your company use biological or genetic resources for research or production? We will check whether the Nagoya Protocol and the Convention on Biological Diversity impose obligations on you.

Product law

In this area, reacting when a problem arises is not enough. You need to act earlier. We advise clients on managing regulatory risk related to products, from composition and labelling, through packaging and environmental obligations, to strategies for entering the EU market and maintaining a secure position within it.

More

They may be interested you

Trade Inspection is challenging my product compliance- how do I defend myself in proceedings and limit my risk?

Client Operator of a discount store chain with a wide non-food assortment The situation Growing EU regulatory requirements on product safety, label...

Case study Product law

Trade Inspection is challenging my product compliance- how do I defend myself in proceedings and limit my risk?

The EU plans to ban PFAS in my products under REACH – how do I build an advocacy strategy and secure an exemption or transition period?

Client Global manufacturer in the technology and industrial sector The situation The pan-European REACH restriction proposal on PFAS covering all n...

Case study Product law

The EU plans to ban PFAS in my products under REACH – how do I build an advocacy strategy and secure an exemption or transition period?

My chemical product contains trace contamination with regulated substances – can I sell it legally and how do I prove this to my counterparty?

Client Manufacturer in the chemical sector The situation Chemical substances can contain trace contamination from other compounds - including subst...

Case study Product law

My chemical product contains trace contamination with regulated substances – can I sell it legally and how do I prove this to my counterparty?

See all

Do you need legal support for an investment or product?

Write or call – we'll answer you specifically
and without unnecessary theory.